Li, J. S., E. L. Eisenstein, H. G. Grabowski, E. D. Reid, B. Mangum, K. A. Schulman, J. V. Goldsmith, M. D. Murphy, R. M. Califf, and D. K. Benjamin Jr. 2007. Economic return of clinical trials performed under the pediatric exclusivity program. Journal of the American Medical Association 297(5):480–488.

Lloyd, I. 2002–2003. New technologies, products in development, and attrition rates: R&D revolution still around the corner. PAREXEL’s pharmaceutical R&D statistical sourcebook. Waltham, MA: PAREXEL International Corporation.

Owens, J. 2007. 2006 drug approvals: Finding the niche. Nature Reviews Drug Discovery 6:99–100.

Platt, R. 2007. Using health plan data to improve post-marketing safety. (accessed July 17, 2007).

Walker, A. 2007. Routine healthcare surveillance is here. (accessed July 17, 2007).

Wilensky, G. R. 2006. Developing a center for comparative effectiveness information. Health Affairs 25(6):w572–w585.

Young, R. C., C. R. Aldige, D. Balma, J. G. Bartlett, E. J. Benz, W. P. Bro, M. A. Caligiuri, B. A. Chabner, W. S. Dalton, N. Davenport-Ennis, M. A. Friedman, W. N. Hait, G. D. Hammond, P. J. Limburg, S. Lippman, H. K. Lyerly, J. L. Marshall, K. H. Mooney, J. M. Olefsky, R. L. Schilsky, E. V. Sigal, and J. W. Yates. 2007. Drug safety and drug efficacy: Two sides of the same coin (A White Paper Report). (accessed May 9, 2007).

Zarin, D. 2007. Resource implications of IOM recommendations for trial registration and results database. (accessed July 17, 2007).

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement